Teriparatide injection - Asahi Kasei Pharma

Drug Profile

Teriparatide injection - Asahi Kasei Pharma

Alternative Names: hPTH - Asahi Kasei Pharma; MN-10-T; PTH injection - Asahi Kasei Pharma; Teribone; Teriparatide acetate injection

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asahi Kasei Pharma Corp
  • Developer Asahi Kasei Pharma Corp; Dong-A ST
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoporosis

Most Recent Events

  • 22 Dec 2016 Asahi Kasei plans a phase III trial for Osteoporosis in Japan (JapicCTI163477)
  • 01 Nov 2016 Asahi Kasei Pharma initiates enrolment in a phase III trial for Osteoporosis in Japan (JapicCTI-163477)
  • 04 Aug 2016 Asahi Kasei plans a phase II trial for Osteoarthritis in Japan (UMIN000022598 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top